Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
0.5033
+0.0075 (1.51%)
Sep 17, 2026, 4:00 PM EDT - Market closed
Evogene Revenue
Evogene had revenue of $347.00K in the quarter ending June 30, 2026, a decrease of -35.02%. This brings the company's revenue in the last twelve months to $1.31M, down -78.78% year-over-year. In the year 2025, Evogene had annual revenue of $3.85M, down -30.91%.
Revenue (ttm)
$1.31M
Revenue Growth
-78.78%
P/S Ratio
4.82
Revenue / Employee
$43,605
Employees
38
Market Cap
7.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.85M | -1.72M | -30.91% |
| Dec 31, 2024 | 5.58M | 2.60M | 87.02% |
| Dec 31, 2023 | 2.98M | 1.31M | 78.03% |
| Dec 31, 2022 | 1.68M | 745.00K | 80.11% |
| Dec 31, 2021 | 930.00K | -110.00K | -10.58% |
| Dec 31, 2020 | 1.04M | 287.00K | 38.11% |
| Dec 31, 2019 | 753.00K | -994.00K | -56.90% |
| Dec 31, 2018 | 1.75M | -1.63M | -48.33% |
| Dec 31, 2017 | 3.38M | -3.16M | -48.30% |
| Dec 31, 2016 | 6.54M | -4.59M | -41.23% |
| Dec 31, 2015 | 11.13M | -3.38M | -23.31% |
| Dec 31, 2014 | 14.51M | -3.07M | -17.46% |
| Dec 31, 2013 | 17.58M | 509.00K | 2.98% |
| Dec 31, 2012 | 17.07M | 2.17M | 14.57% |
| Dec 31, 2011 | 14.90M | 2.34M | 18.61% |
| Dec 31, 2010 | 12.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 4.70M |
| Ensysce Biosciences | 4.50M |
| Traws Pharma | 2.73M |
| Exicure | 500.00K |
| Soligenix | 2.34K |
EVGN News
- 17 days ago - Evogene responds to latest communication from L.I.A. Pure Capital, Invest-Pro - TheFly
- 17 days ago - Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward - PRNewsWire
- 22 days ago - EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026 - Business Wire
- 23 days ago - Evogene (EVGN) Q2 2026 Earnings Call Transcript - The Motley Fool
- 23 days ago - Evogene’s director nominees recommended by ISS and Glass Lewis - TheFly
- 23 days ago - Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees - PRNewsWire
- 4 weeks ago - Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35% - AlphaStreet
- 4 weeks ago - Evogene Q2 Loss Narrows As AI Transformation Drives Strategic Progress - Nasdaq